Organogenesis Upgraded to Buy as Regenerative Medicine Gains Momentum
Wall Street Zen has upgraded Organogenesis (NASDAQ: ORGO) to a 'Buy' rating, signaling increased confidence in the regenerative medicine specialist's market position. This move comes amid a broader wave of optimistic re-ratings for mid-cap growth stocks across multiple sectors, including oilfield services and software.